Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was the target of a large drop in short interest in November. As of November 30th, there was short interest totalling 1,108,395 shares, a drop of 28.5% from the November 15th total of 1,549,997 shares. Currently, 8.3% of the company’s stock are sold short. Based on an average daily trading volume, of 417,516 shares, the short-interest ratio is presently 2.7 days.

Several equities analysts recently commented on ANTH shares. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Tuesday, October 10th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. Finally, ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $5.11.

Anthera Pharmaceuticals (NASDAQ ANTH) opened at $1.55 on Friday. Anthera Pharmaceuticals has a 1 year low of $1.20 and a 1 year high of $17.04.

Anthera Pharmaceuticals (NASDAQ:ANTH) last posted its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.32. During the same quarter in the previous year, the business earned ($4.85) EPS. equities research analysts forecast that Anthera Pharmaceuticals will post -3.14 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Anthera Pharmaceuticals stock. Wedbush Securities Inc. boosted its holdings in shares of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by 75.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 73,764 shares of the biopharmaceutical company’s stock after buying an additional 31,800 shares during the quarter. Wedbush Securities Inc. owned 0.68% of Anthera Pharmaceuticals worth $106,000 at the end of the most recent reporting period. 16.24% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Anthera Pharmaceuticals, Inc. (ANTH) Short Interest Update” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with's FREE daily email newsletter.